ALFA Finder| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 15.2 | 12.6 | 14.4 |
| Other income | 0.7 | 0.0 | 0.0 |
| Total income | 15.9 | 12.6 | 14.4 |
| Profit before exceptional items & tax | 5.2 | 2.7 | 4.3 |
| Profit before tax | 5.2 | 2.7 | 4.3 |
| Net profit | 3.8 | 2.0 | 3.2 |
| Operating margin | 32.7% | 21.4% | 29.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +18.70% |
|---|---|
| Net profit, quarter on quarter | +90.00% |
| Revenue, year on year | +5.60% |
| Operating profit, year on year | +4.70% |
| Operating profit, quarter on quarter | +66.70% |
BSE results filing, BSE: 544629. Figures extracted from the filing.
Ravelcare Ltd: key numbers
- Share price
- ₹98.00
- Market cap
- ₹67.22 Cr
- Revenue (annual)
- ₹26.95 Cr
- Net profit (annual)
- ₹5.15 Cr
- P/E (TTM)
- 13.0×Sector 40.7×
- Promoter holding
- 72.94%
- FII holding
- 1.82%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ravelcare Ltd
All →Ravelcare Board Meeting Date
Ravelcare will meet on November 12, 2026 to consider unaudited half-year results. The trading window stays closed until 48 hours after the results declaration.
Ravelcare Other Announcement
Ravelcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations. This is a routine compliance disclosure.
Ravelcare Annual General Meeting
Ravelcare Ltd submitted the proceedings of its 8th AGM held on September 23, 2026. Items covered adoption of audited FY26 financials and re-appointment of the MD, WTD, and a retiring director.
Ravelcare Annual Report
Ravelcare Limited has filed its Annual Report for the fiscal year 2025-26, along with the notice for its 8th Annual General Meeting.
Ravelcare Product Launch
Ravelcare Limited launched the 'Ravel PRO' and AI diagnostic skincare range to expand its market presence. These new products are available across major e-commerce platforms.
Ravelcare Management Change
Ravelcare Limited has announced the re-appointment of its Executive Directors, Mr. Ayush Varma and Mr. Maheshkumar Varma, along with Secretarial Auditor M/s. VTSN & Associates LLP.